GLP-1 Shortage 2026: Wegovy, Zepbound, Ozempic Availability & What to Do

The GLP-1 supply crisis: where we stand in 2026

Since 2022, GLP-1 medications have faced recurring shortages that have frustrated patients and providers alike. The unprecedented demand for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) has repeatedly outpaced manufacturing capacity.

As of 2026, the situation has improved significantly. Both Novo Nordisk and Eli Lilly have invested billions in expanding production. Most doses of Wegovy and Zepbound are now available through pharmacies. However, intermittent supply disruptions still occur, particularly for specific dose strengths and in certain geographic regions.

Current availability by medication (2026)

Wegovy (semaglutide 2.4mg)

• Most dose strengths (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg) are now available
• Occasional supply disruptions for the 2.4mg target dose in some regions
• Novo Nordisk has expanded manufacturing in Denmark and the US
• Supply is expected to stabilize fully by late 2026

Ozempic (semaglutide for diabetes)

• Generally available, though intermittent shortages occur
• Some patients have been prescribed Ozempic off-label for weight loss, contributing to shortages for diabetes patients
• Novo Nordisk has implemented measures to prioritize diabetes patients

Zepbound (tirzepatide for weight loss)

• Most doses available, with improving supply throughout 2026
• Introduction of single-dose vials (in addition to auto-injector pens) has improved supply flexibility
• Certain dose strengths may still experience tight supply in some markets
• Eli Lilly has significantly expanded manufacturing capacity

Mounjaro (tirzepatide for diabetes)

• Generally available with occasional regional disruptions
• Supply has improved significantly since 2024

Why GLP-1 shortages happen

The GLP-1 shortage is not a simple manufacturing problem. It is a complex supply chain challenge involving multiple factors:

1. Explosive demand growth

GLP-1 searches have grown 25-fold since the medications launched. Zepbound surpassed Ozempic in US search volume in January 2026. The market grew far faster than anyone predicted, including the manufacturers themselves.

2. Manufacturing complexity

GLP-1 medications are injectable biologics that require specialized manufacturing facilities. Unlike simple pills, injection pens require precise dosing mechanisms, sterile filling, and quality testing. Expanding a single manufacturing line can take 2 to 3 years.

3. Injection pen component shortages

The auto-injector pens used for Wegovy and Zepbound require specialized components including springs, needles, and glass cartridges. Global supply chain disruptions have periodically limited the availability of these components.

4. Cold chain logistics

GLP-1 medications must be stored and transported at refrigerated temperatures. This limits distribution speed and creates bottlenecks in the cold chain logistics network.

5. Off-label prescribing

Some of the shortage has been driven by people using GLP-1 medications off-label for mild weight loss or cosmetic purposes, reducing availability for patients who meet the FDA criteria.

Compounded GLP-1 alternatives: what you need to know

During the shortage, the FDA has allowed compounding pharmacies to produce semaglutide and tirzepatide. Compounded medications are made by licensed pharmacies from the same active pharmaceutical ingredient (API) as brand-name products.

Pros of compounded GLP-1 medications

• Significantly cheaper: $99 to $300 per month vs. $1,000+ for brand-name
• Generally available even when brand-name is in shortage
• Accessible through telehealth providers with online consultations
• Same active ingredient (semaglutide or tirzepatide)
• Shipped directly to your door

What to watch out for

• Only use licensed US compounding pharmacies — avoid unregulated online sellers
• Never buy "research grade" semaglutide — it is not intended for human use
• Ensure the provider requires a legitimate medical consultation and prescription
• Verify the pharmacy is licensed in your state
• Be cautious of prices that seem too good to be true

Reputable telehealth providers offer compounded semaglutide starting at $99 per month and compounded tirzepatide starting at $125 per month, with medical consultations, lab work, and ongoing provider support included.

What to do if you cannot find your GLP-1 medication

Step 1: Call multiple pharmacies

Availability varies by pharmacy and region. Call at least 3 to 5 pharmacies in your area, including both chain pharmacies (CVS, Walgreens, Walmart) and independent pharmacies. Ask specifically about the dose you need.

Step 2: Ask about dose alternatives

If your exact dose is unavailable, ask your provider if you can temporarily use a different dose. For example, if 1.0mg semaglutide is out of stock, your provider may recommend using two 0.5mg pens or adjusting to 0.5mg temporarily.

Step 3: Consider switching medications

If semaglutide is unavailable, tirzepatide may be in stock (and vice versa). Both are effective GLP-1 medications. Talk to your provider about switching. Note that you will need to re-titrate when switching.

Step 4: Try compounded alternatives

If brand-name medication is consistently unavailable, compounded semaglutide or tirzepatide through a telehealth provider is a reliable alternative. These are available nationwide and shipped to your door.

Step 5: Do not stop abruptly

If you absolutely cannot access medication for a period, do not panic. Missing 1 to 2 weeks will not cause immediate weight regain, though appetite may start to return. Resume as soon as possible and contact your provider for guidance.

How to prevent future supply disruptions

• Refill early: Request your refill 1 to 2 weeks before you run out
• Use mail-order pharmacies: They often have better supply than retail pharmacies
• Build a relationship with one pharmacy: They can hold stock for you
• Keep a backup supply: If possible, keep 1 to 2 extra doses on hand
• Consider compounded as backup: Have a telehealth provider lined up in case brand-name is unavailable
• Stay in touch with your provider: They can help you navigate shortages quickly

Frequently asked questions

Is there still a GLP-1 shortage in 2026?

As of 2026, GLP-1 availability has improved significantly but is not fully resolved. Most doses of Wegovy and Zepbound are now available, but certain dose strengths may still experience intermittent supply disruptions. Compounded semaglutide and tirzepatide remain available through telehealth providers.

What should I do if my pharmacy is out of GLP-1 medication?

Call multiple pharmacies in your area, ask your doctor about equivalent medications, consider compounded semaglutide through telehealth providers, or ask about switching from semaglutide to tirzepatide (or vice versa). Do not skip doses without consulting your provider.

Is compounded semaglutide safe during the shortage?

Compounded semaglutide from licensed US compounding pharmacies and telehealth providers is regulated and generally safe. The FDA allows compounding of drugs in shortage. However, avoid unregulated online pharmacies and 'research grade' semaglutide, which can be dangerous.

Why do GLP-1 shortages keep happening?

GLP-1 shortages are caused by manufacturing capacity limits, explosive demand growth, complex supply chains, and the need for specialized injection pen components. Novo Nordisk and Eli Lilly have expanded production but demand continues to outpace supply for certain doses.

Conclusion

The GLP-1 shortage situation has improved dramatically in 2026, but intermittent supply disruptions can still occur. By staying proactive — refilling early, calling multiple pharmacies, and having a backup plan with compounded alternatives — you can ensure uninterrupted access to your medication. If you are struggling to find GLP-1 medication locally, telehealth providers offer compounded semaglutide and tirzepatide starting at $99 per month, shipped directly to your door. Check your eligibility today to get started.